Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine
about
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.Origin and proliferation of multiple-drug resistance in bacterial pathogensAssessment of molecular typing methods to determine invasiveness and to differentiate clones of Streptococcus pneumoniaePre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.Role of conjugative elements in the evolution of the multidrug-resistant pandemic clone Streptococcus pneumoniaeSpain23F ST81Genetic Stabilization of the Drug-Resistant PMEN1 Pneumococcus Lineage by Its Distinctive DpnIII Restriction-Modification SystemPromiscuous signaling by a regulatory system unique to the pandemic PMEN1 pneumococcal lineage.Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.Differences in genotype and virulence among four multidrug-resistant Streptococcus pneumoniae isolates belonging to the PMEN1 clone.Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer.Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United StatesSerotype and genotype distribution among invasive Streptococcus pneumoniae isolates in Colombia, 2005-2010.Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniaeCommunity prescribing and resistant Streptococcus pneumoniae.Failure to control an outbreak of multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: emergence and ongoing transmission of a fluoroquinolone-resistant strain.Efflux-mediated antimicrobial resistance.Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.Whole Genome Sequencing of 39 Invasive Streptococcus pneumoniae Sequence Type 199 Isolates Revealed Switches from Serotype 19A to 15BAntimicrobial resistance in the hospital setting: impact, trends, and infection control measures.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.Geminofloxacin for the management of community-acquired respiratory tract infections.Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa.Role of macrolide therapy in chronic obstructive pulmonary disease.Emerging drugs for pneumococcal pneumonia.Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.Serotyping, Antibiotic Susceptibility and Related Risk Factors Aspects of Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy School Students.The treatment of acute bacterial sinusitis: no change is good medicineProbing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IVMolecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spreadHigh-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium.[Prevention in the elderly: position paper on pneumococcal vaccinations. Results of an expert workshop on 15 November 2013 in Cologne, Germany].High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis.Genotype replacement within serotype 23F Streptococcus pneumoniae in Beijing, China: characterization of serotype 23F.
P2860
Q24815187-A978934B-BDEF-45FA-909F-312E2988A1BDQ27023284-642A883F-EF2E-4495-8A66-88B59A3D6433Q28756312-9AA6758C-B191-4F78-8C08-531956807F2DQ28768295-9D0EE476-053A-4AF6-BA75-C231F03111A9Q30251593-8D70FEA6-B690-45C0-A580-79151CD1A646Q30374128-4F917975-1E93-40AF-B090-C615DAE639B0Q30375739-EACFEE05-6EBF-49A1-81A1-028009E6F6AEQ30402403-39DF3794-27D2-4134-BD99-5D771D84BB8CQ33264145-167C7B8D-ADD6-4C41-83AF-01E1F7401A42Q33770218-14220A0F-6016-45DA-A662-78A0536F2284Q33806725-E64C6018-924C-4563-AEDB-9225883771FFQ34113640-3794D8DA-EB21-41F7-B281-D9D45827B1F0Q34352053-99F7F1B2-2235-4782-B0BD-33A613C599BBQ34509660-3AC8149D-8086-4372-8685-C8DA65985D88Q34510471-A192D9F6-FBD1-4A09-A0AE-148F29912730Q35084987-EFD630BC-647E-4E4E-94BD-2C569312BDEBQ36009308-DE8B03F3-D907-47C4-8857-10F211FEDFBAQ36009361-F5A73A97-7C68-4C97-BBA0-E2914982D137Q36082806-9AC637E8-7DAB-4614-BAB9-E7BF8D9C5EFCQ36138147-31F3BCD4-7433-4E09-9448-17E3A2EA4B8EQ36156085-BC193602-8357-43DA-B9F9-38BD21EF4F31Q36238637-2E074A34-0205-4841-84D0-E36C262BA122Q36264490-579F47C4-0A34-4EFB-ABB8-C2244E8E5059Q36337074-00F67C5C-2CC5-4EE9-A27C-3EEFEA836AE1Q36482793-5437381C-D23F-4A35-9A28-C0A9A21857ACQ36724349-DEB93B5E-FDAA-41B7-B2B0-5C860EC4EA44Q37191555-62153BBC-B946-404F-9712-345C7868543BQ37319950-03D8AFBA-CB0D-4884-A063-B2EC709FB5D0Q37864327-B7F68780-7557-4636-AADE-9F652DC23CA4Q37998398-A5F5BB20-EBBD-4CC1-8E84-C0E09CF21AE5Q38446646-5D4AB32C-2206-4745-BFDC-6470FDF4F0F5Q38460335-295D4E19-282E-4568-A428-EFC930A34685Q38984686-9B31B00C-0473-47D4-BD56-67513E6160A1Q42098440-7C52AF63-CCC6-4115-B9AA-E3A08D9A18B5Q42111571-67111836-048F-465D-85A2-957BC9B114F2Q42112596-8AA4D5A1-06D5-41CC-8A2B-8A70BCD4F431Q43234730-D1D26659-AF91-4FE1-9DF1-960A266A2AACQ43447838-D2D57736-EF05-420D-B070-3392E24CF78CQ44093671-5A2AA699-7BC1-4EA2-9E97-7765A9F4D41CQ44252372-3A98D3C7-8D93-402C-9319-09E85FF73EC3
P2860
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Levofloxacin-resistant invasiv ...... conjugate pneumococcal vaccine
@en
Levofloxacin-resistant invasiv ...... onjugate pneumococcal vaccine.
@nl
type
label
Levofloxacin-resistant invasiv ...... conjugate pneumococcal vaccine
@en
Levofloxacin-resistant invasiv ...... onjugate pneumococcal vaccine.
@nl
prefLabel
Levofloxacin-resistant invasiv ...... conjugate pneumococcal vaccine
@en
Levofloxacin-resistant invasiv ...... onjugate pneumococcal vaccine.
@nl
P2093
P2860
P1476
Levofloxacin-resistant invasiv ...... conjugate pneumococcal vaccine
@en
P2093
Bernard Beall
Cynthia G Whitney
James Jorgensen
Lesley McGee
Mathias W R Pletz
Richard R Facklam
P2860
P304
P356
10.1128/AAC.48.9.3491-3497.2004
P407
P577
2004-09-01T00:00:00Z